Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
FIERCE-22
A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
- NCT03123055 ↗
- Terminated
- Rainier Therapeutics
- Focused
We haven't built an HCP commentary report on FIERCE-22 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FIERCE-22 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Locally Advanced or Metastatic Urothelial Cell Carcinoma; Urinary Bladder Disease; Urological Diseases
- Interventions
- B-701; Pembrolizumab
- Arms
- B-701 (vofatamab) · Experimental
- B-701 (vofatamab) plus pembrolizumab · Experimental
- Enrollment
- 28
- Primary outcomes
- Number of Participants With Dose Limiting Toxicities Within a Period of 35 Days
- Number of Subjects Experiencing Adverse Events (AEs and SAEs)
- Efficacy of B-701 (Vofatamab) Plus Pembrolizumab Measured by ORR
- Sponsor
- Rainier Therapeutics
- Start
- Apr 20, 2017
- Primary completion
- Dec 1, 2019
- Results posted
- Yes
- Registry record
- NCT03123055 · updated Mar 18, 2020